Route 92 Medical Announces Appointment of Raj Denhoy as Chief Financial OfficerWEST JORDAN, Utah, May 18, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Raj Denhoy to the role of Chief Financial Officer (CFO) effective today.
Route 92 Medical Announces $50 Million Growth FinancingNew investor Sectoral Asset Management joins growth financing round to support acceleration of commercial growth
Route 92 Medical Enrolls First Patient in SUMMIT RISE StudySUMMIT RISE is expected to enroll up to 500 patients to evaluate the performance of Route 92 Medical’s neurovascular intervention device portfolio
Route 92 Medical Appoints Medtech Industry Leader Pat Mackin to its Board of DirectorsSAN MATEO, Calif. and WEST JORDAN, Utah, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the election of Pat Mackin to its Board of Directors. His appointment brings deep commercial, operational, business development, and executive leadership experience in medical technology companies to Route 92 Medical’s Board of Directors as the company continues to grow its differentiated portfolio of neurovascular solutions globally.
Route 92 Medical Files Patent Infringement Suit Against BaltSAN MATEO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, filed a patent infringement lawsuit against Balt USA, LLC (Balt) alleging infringement of five U.S. patents held by Route 92 Medical that protect the Tenzing® delivery technology. The complaint was filed on August 6, 2025, in the U.S. District Court for the District of Delaware.
Real World Data Supports Results of Route 92 Medical’s SUMMIT MAX Clinical TrialCompany also announces new 500-patient SUMMIT RISE study at the Society of NeuroInterventional Surgery annual meeting
Route 92 Medical Appoints Medtech Industry Veterans Mitch Hill and Lucas Buchanan to its Board of DirectorsSAN MATEO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the election of Mitch Hill and Lucas Buchanan to its Board of Directors. The appointment of these industry veterans will bring critical operational and financial experience to the Route 92 Medical Board of Directors as the company continues to commercialize its differentiated portfolio of neurovascular solutions.
Route 92 Medical Announces Settlement of Patent Litigation with Q’Apel MedicalSAN MATEO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced that the dispute between Route 92 Medical and Q’Apel Medical has been resolved. Route 92 Medical initially filed suit against Q’Apel Medical in the U.S. District Court for the District of Delaware in October 2024 alleging infringement of five U.S. patents protecting its portfolio of Tenzing® delivery catheters by the Q’Apel Hippo aspiration system and Cheetah delivery tool. Q’Apel Medical has removed the Hippo - Cheetah product from the market permanently.
Route 92 Medical Receives Australian Therapeutic Goods Administration Approval for its Portfolio of Neurovascular Interventional Products for Treating Patients with Acute Ischemic StrokeSAN MATEO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced approval from the Australian Therapeutic Goods Administration (TGA) for its innovative neurovascular intervention portfolio. Within this portfolio are the first .088” super bore reperfusion systems to be approved for use in Australia, including the FreeClimb® 88 catheter powered by Tenzing® technology and the Monopoint®-based HiPoint® 88 super-bore catheter.
Route 92 Medical Gains EU and MDSAP Certification for its Neurovascular Stroke-Intervention-Focused Product PortfolioSAN MATEO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the achievement of European Union approval (CE mark) under the EU Medical Device Regulation (MDR) 2017/745 for its innovative line of neurovascular intervention products. The company also announced clearance under the MDSAP program which gives broad access to international markets.
Route 92 Medical Files Patent Infringement Suit Against Q’Apel MedicalSAN MATEO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today filed a patent infringement lawsuit against Q’Apel Medical alleging infringement of five U.S. patents held by Route 92 Medical, which protect the Tenzing® delivery catheter. The complaint was filed October 7, 2024, in the United States District Court for the District of Delaware.
Route 92 Medical Announces Commercial Launch of FreeClimb 88 Catheter SystemSAN MATEO, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced commercial launch of the FreeClimb® 88 catheter system comprising the FreeClimb 88 catheter and the Tenzing® 8 delivery catheter, all designed to work with the Base Camp® sheath. The FDA 510(k) cleared FreeClimb 88 catheter system offers reliable navigation through tortuous anatomy in the neurovasculature and is available in 125 cm and 132 cm lengths to provide clinicians with the flexibility they need to reach their targeted locations.
Route 92 Medical Announces FDA 510(k) Clearance for FreeClimb 54 Reperfusion SystemSAN MATEO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced receipt of 510(k) clearance for the FreeClimb® 54 reperfusion system, comprised of the FreeClimb 54 aspiration catheter paired with a Tenzing® 5 delivery catheter. This new system is part of a growing portfolio of neurovascular devices from Route 92 Medical designed to work harmoniously as a complete endovascular thrombectomy solution to address a broad range of neurovascular interventions.
Route 92 Medical Announces Completion of Enrollment in the SUMMIT MAX Clinical TrialRandomized controlled trial designed to evaluate the safety and effectiveness of the Route 92 Medical 0.088” HiPoint Reperfusion Catheter, part of the Monopoint Reperfusion System
Route 92 Medical Announces the 100th Patent for its Neurovascular Intervention PortfolioGlobal and rapidly growing patent portfolio supports Route 92 Medical’s ongoing innovation as the company works to address critical unmet needs in stroke treatment
Route 92 Medical Raises Over $31 Million in Oversubscribed Series F Equity Financing to Accelerate its Commercialization into the Rapidly Growing Stroke Treatment MarketSAN MATEO, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced it has raised over $31 million in a Series F financing to accelerate the commercial adoption of a neurovascular intervention portfolio focused on acute ischemic stroke. The oversubscribed capital raise was led by existing venture capital investors: U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and The Vertical Group.
Route 92 Medical Announces Impressive Clinical Results for its Tenzing® Technology.Multicenter clinical study showcases how Tenzing® technology is improving neurovascular intervention outcomes
Route 92 Medical Announces Appointment of Jonathan Kennedy as Chief Financial OfficerSAN MATEO, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Jonathan Kennedy to the role of Chief Financial Officer. In this role, Jonathan will be responsible for overseeing all financial management for the company, reporting directly to Chief Executive Officer Tony Chou.
Route 92 Medical Announces Publication of a Retrospective Study in the Interventional Neuroradiology JournalStudy shows FreeClimb 70 Reperfusion System, powered by the Tenzing 7 delivery catheter, enables neurointerventionalists to address critical unmet needs in ischemic stroke treatment
Route 92 Medical Announces Appointment of Chris Hartman as Chief Commercial OfficerSAN MATEO, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the appointment of Chris Hartman to the role of Chief Commercial Officer. In this role, Chris will be responsible for continuing to build the sales and marketing organizations to grow Route 92 Medical’s global commercial footprint.
Route 92 Medical Receives the First FDA Clearance for a Complete Stroke Treatment SystemThe FreeClimb 70 Reperfusion System, powered by the Tenzing 7 delivery catheter, enables neurointerventionalists to address critical unmet needs in ischemic stroke treatment
Route 92 Medical Announces the 80th Patent for Monopoint Operating Platform
Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the company’s 80th global issued patent for its Monopoint® Operating Platform. The Monopoint® Operating Platform is the only neurointervention platform designed to streamline delivery of large and super-bore catheters for aspiration at the most common stroke targets. The single-platform system is designed for efficient and effective neurovascular intervention with a design that eliminates length challenges and provides a single point of control for enhanced single-operator capability.
Route 92 Medical Announces Expansion to New Manufacturing Site in Salt Lake City, UtahSAN MATEO, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced expansion to a new high-volume manufacturing site in Salt Lake City, Utah. This 40,000 square foot site allows Route 92 to substantially augment its manufacturing capabilities while serving as a clinician training and education center. Route 92 will maintain its headquarters in San Mateo, California, sustaining its existing product manufacturing capabilities and research and development center for the design and production of new products.
